FDA Approves Pirtobrutinib for Frontline Treatment of Chronic Lymphocytic Leukemia
The FDA approved pirtobrutinib, sold as Jaypirca by Eli Lilly, on October 2, 2026, for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without the 17p deletion. The approval expands the drug's use into the frontline setting, giving doctors a new option for patients at the start of treatment. The FDA approved 18 new oncology therapies in 2026.
The U.S. Food and Drug Administration approved pirtobrutinib, sold under the brand name Jaypirca by Eli Lilly and Company, on October 2, 2026, for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who do not have a known 17p deletion.
The approval marks a significant expansion of the drug's use into the frontline setting, giving oncologists a new treatment option for patients at the start of their CLL or SLL diagnosis rather than only after other therapies have failed.
Pirtobrutinib is a non-covalent BTK inhibitor, a class of drugs that works by blocking a protein called Bruton's tyrosine kinase, which cancer cells rely on to grow and survive. Unlike earlier BTK inhibitors, pirtobrutinib is designed to remain effective even in patients whose cancer has developed resistance to covalent BTK inhibitors.
The October 2 approval follows the FDA's broader oncology regulatory activity in 2026, during which the agency approved 18 new cancer therapies, consisting of 11 small molecules and 7 biologics. Bispecific antibodies and antibody-drug conjugates were the most prominent drug classes among the year's approvals.
The FDA met approximately 94 percent of its Prescription Drug User Fee Act goal dates for oncology reviews in 2026, with a median review time of 6.2 months for priority submissions.
CLL is the most common type of leukemia in adults in the United States, with tens of thousands of new cases diagnosed each year. The disease progresses slowly in many patients but requires treatment when it advances.
Eli Lilly has not yet announced pricing details for the frontline indication.
